Targeting the CSF1/CSF1R axis in tenosynovial giant cell tumor: from microenvironmental dependency to therapeutic escape

Tenosynovial giant cell tumor (TGCT) is a rare, benign neoplasm with locally aggressive potential, characterized by an imbalance between a relatively small neoplastic cell population and an abundant inflammatory microenvironment. Dysregulated CSF1 expression by neoplastic cells promotes the recruitment and expansion of CSF1R-expressing macrophages, creating a tumor ecosystem dependent on CSF1/CSF1R signaling. This biological vulnerability has been translated into targeted therapies, with pexidartinib and vimseltinib demonstrating clinically meaningful tumor responses in patients with unresectable or symptomatic TGCT. However, these responses highlight a distinctive translational challenge: inhibition of a major microenvironmental dependency can produce substantial tumor regression without necessarily eliminating the underlying neoplastic population, which does not express CSF1R. This offers a biological rationale for considering residual disease as potentially enriched in neoplastic cells after macrophage-directed therapy. Here, we provide a state-of-the-art overview of treatment efficacy, resistance mechanisms and the translational trajectory of CSF1/CSF1R targeting in TGCT, from biological rationale to pharmacological optimization and patient-relevant clinical benefit. Particular attention is given to therapeutic escape, which may differ from target resistance mutations observed in other oncogene-driven tumors. We propose a conceptual framework distinguishing pharmacological escape, biological escape and clinical failure, while emphasizing that most proposed compensatory mechanisms remain hypothetical in TGCT. Finally, we discuss the need for dynamic biomarkers, longitudinal tissue analyses and patient-derived translational models to better understand response durability and guide treatment sequencing. Therefore, TGCT represents an informative model for precision oncology directed not only against tumor cells, but also against the tumor microenvironment on which they depend.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-16
DOI
https://doi.org/10.3389/fmed.2026.2030736
Primary Topic
Musculoskeletal synovial abnormalities and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting the CSF1/CSF1R axis in tenosynovial giant cell tumor: from microenvironmental dependency to therapeutic escape

Koffi Kowouvi, Mariella Spalato Ceruso
2 links
Frontiers in Medicine
Musculoskeletal synovial abnormalities and treatments
article

Targeting the CSF1/CSF1R axis in tenosynovial giant cell tumor: from microenvironmental dependency to therapeutic escape

Koffi Kowouvi, Mariella Spalato Ceruso
article en

Abstract

Tenosynovial giant cell tumor (TGCT) is a rare, benign neoplasm with locally aggressive potential, characterized by an imbalance between a relatively small neoplastic cell population and an abundant inflammatory microenvironment. Dysregulated CSF1 expression by neoplastic cells promotes the recruitment and expansion of CSF1R-expressing macrophages, creating a tumor ecosystem dependent on CSF1/CSF1R signaling. This biological vulnerability has been translated into targeted therapies, with pexidartinib and vimseltinib demonstrating clinically meaningful tumor responses in patients with unresectable or symptomatic TGCT. However, these responses highlight a distinctive translational challenge: inhibition of a major microenvironmental dependency can produce substantial tumor regression without necessarily eliminating the underlying neoplastic population, which does not express CSF1R. This offers a biological rationale for considering residual disease as potentially enriched in neoplastic cells after macrophage-directed therapy. Here, we provide a state-of-the-art overview of treatment efficacy, resistance mechanisms and the translational trajectory of CSF1/CSF1R targeting in TGCT, from biological rationale to pharmacological optimization and patient-relevant clinical benefit. Particular attention is given to therapeutic escape, which may differ from target resistance mutations observed in other oncogene-driven tumors. We propose a conceptual framework distinguishing pharmacological escape, biological escape and clinical failure, while emphasizing that most proposed compensatory mechanisms remain hypothetical in TGCT. Finally, we discuss the need for dynamic biomarkers, longitudinal tissue analyses and patient-derived translational models to better understand response durability and guide treatment sequencing. Therefore, TGCT represents an informative model for precision oncology directed not only against tumor cells, but also against the tumor microenvironment on which they depend.

Frontiers in MedicineVol. 13
Institut de Cancérologie de Lorraine (FR), Cibles thérapeutiques, formulation et expertise préclinique du médicament (FR), Université de Lorraine (FR)
Good health and well-being
Musculoskeletal synovial abnormalities and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon